Tianjin Chase Sun Pharmaceutical Co.,Ltd (SHE:300026)
China flag China · Delayed Price · Currency is CNY
3.610
+0.040 (1.12%)
At close: Feb 3, 2026

SHE:300026 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Jan '23 Dec '21 Dec '20
Operating Revenue
5,4645,7576,0256,6037,6566,463
Other Revenue
26.2426.2484.3147.4414.6325.37
5,4905,7836,1096,6507,6716,488
Revenue Growth (YoY)
-2.44%-5.34%-8.14%-13.30%18.22%29.69%
Cost of Revenue
2,6542,7932,8272,8263,2672,858
Gross Profit
2,8362,9893,2823,8244,4033,630
Selling, General & Admin
2,4182,5342,4632,7513,0542,648
Research & Development
202.07223.45209.81230.85196.59177.03
Other Operating Expenses
54.448.7441.461.7276.441.87
Operating Expenses
2,7512,8872,7673,1003,4012,896
Operating Income
85.46102.42515.52724.421,002733.98
Interest Expense
-19.17-44.86-61.57-69.67-50.1-30.07
Interest & Investment Income
11.7817.3119.3114.1811.3812.03
Currency Exchange Gain (Loss)
3.923.922.4117.62-6.34-29.34
Other Non Operating Income (Expenses)
-48.14-22.2-18.49-35.65-26.8621.11
EBT Excluding Unusual Items
33.8456.59457.19650.91930.58707.71
Impairment of Goodwill
-17.34-17.34-23.52--58.18-
Gain (Loss) on Sale of Investments
-7.4-5.63-1.4--22.98-
Gain (Loss) on Sale of Assets
1.241.081.060.01-2.870.03
Asset Writedown
-66.68-30.33-4.05-2.36-9.35-24.3
Other Unusual Items
49.6249.62177.5467.8216.99-0.03
Pretax Income
-6.7353.98606.82716.37854.18683.41
Income Tax Expense
70.7931.04105.2595.14183.32123.73
Earnings From Continuing Operations
-77.5222.95501.57621.23670.85559.68
Minority Interest in Earnings
11.4-1.485.063.0116.4713.71
Net Income
-66.1321.47506.63624.24687.32573.39
Net Income to Common
-66.1321.47506.63624.24687.32573.39
Net Income Growth
--95.76%-18.84%-9.18%19.87%42.45%
Shares Outstanding (Basic)
2,0612,1472,9802,9732,9883,018
Shares Outstanding (Diluted)
2,0612,1472,9802,9732,9883,018
Shares Change (YoY)
-27.37%-27.97%0.26%-0.53%-0.98%4.96%
EPS (Basic)
-0.030.010.170.210.230.19
EPS (Diluted)
-0.030.010.170.210.230.19
EPS Growth
--94.12%-19.05%-8.70%21.05%35.71%
Free Cash Flow
705.19659.121,183-24.93-285.85-367.12
Free Cash Flow Per Share
0.340.310.40-0.01-0.10-0.12
Dividend Per Share
0.0300.0300.0300.0300.0400.040
Dividend Growth
----25.00%--20.00%
Gross Margin
51.65%51.69%53.73%57.50%57.40%55.95%
Operating Margin
1.56%1.77%8.44%10.89%13.07%11.31%
Profit Margin
-1.20%0.37%8.29%9.39%8.96%8.84%
Free Cash Flow Margin
12.84%11.40%19.36%-0.38%-3.73%-5.66%
EBITDA
364.62387.15807.69974.091,217923.97
EBITDA Margin
6.64%6.69%13.22%14.65%15.86%14.24%
D&A For EBITDA
279.16284.74292.17249.67214.2189.99
EBIT
85.46102.42515.52724.421,002733.98
EBIT Margin
1.56%1.77%8.44%10.89%13.07%11.31%
Effective Tax Rate
-57.49%17.34%13.28%21.46%18.11%
Revenue as Reported
5,4905,7836,1096,6507,6716,488
Advertising Expenses
-8.69.1512.621.2119.45
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.